Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Phosphoinositides and PIPs

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...

Protein-protein Interfaces

Protein-protein Interfaces

Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Potent and Selective Quinolone-Based PTPN22 Inhibitor with Improved Immunotherapeutic Activity.

Journal of medicinal chemistry·2026

Same author

Timing of the first dressing change after CVC insertion in pediatric critically ill patients: a randomized controlled, non-inferiority trial.

Scientific reports·2026

Same author

Phosphatases of regenerating liver downregulate PTEN to promote tumorigenesis.

Biochemical Society transactions·2026

Same author

DCPM-ADMET: fusion of dual-component pre-trained model and molecular fingerprints to enhance drug ADMET properties prediction.

Journal of cheminformatics·2026

Same author

Early detection of heart failure using trend similarity metrics combined with hybrid deep learning based on real-world health monitoring data.

Journal of the Royal Society, Interface·2026

Same author

Author Correction: Discovery of chirally dependent protein modifications by D- and L-2-hydroxyglutarates.

Nature chemistry·2026

Search research articles

Related Experiment Video

Updated: Sep 21, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

PTPN22: structure, function, and developments in inhibitor discovery with applications for immunotherapy.

Brenson A Jassim¹, Jianping Lin¹, Zhong-Yin Zhang¹

¹Department of Medicinal Chemistry and Molecular Pharmacology, Purdue Institute for Drug Discovery, West Lafayette, IN, USA.

Expert Opinion on Drug Discovery

|May 31, 2022

Summary

This summary is machine-generated.

Targeting PTPN22 (protein tyrosine phosphatase 22) with small molecule inhibitors shows promise for enhancing cancer immunotherapy. These inhibitors could improve responses to existing treatments like checkpoint inhibition and adoptive T cell therapy.

Keywords:

Autoimmune disorders LYP PTPN22 PTPN22 inhibitors immunotherapy

More Related Videos

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Related Experiment Videos

Last Updated: Sep 21, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Area of Science:

Immunology
Cancer Biology
Pharmacology

Background:

Current immunotherapies like immune checkpoint inhibition and adoptive T cell therapy face limitations in patient response and toxicity.
Novel targets and strategies are needed to maximize the potential of cancer immunotherapy.
Protein tyrosine phosphatase 22 (PTPN22) is a key regulator of T cell signaling and proliferation, emerging as a druggable target.

Purpose of the Study:

To review the structure and function of PTPN22.
To provide insights into the development of small molecule PTPN22 inhibitors.
To explore the potential of PTPN22 inhibition in combination with current immunotherapies.

Main Methods:

Literature review focusing on PTPN22.
Analysis of recent advances in small molecule PTPN22 inhibitor development.
Evaluation of PTPN22 inhibition's synergistic potential with existing immunotherapies.

Main Results:

PTPN22 inhibitors demonstrate significant potential to enhance the efficacy of current immunotherapies.
Small molecule inhibitors targeting PTPN22 can synergize with immune checkpoint inhibition and adoptive cell transfer.
Recent progress has been made in developing small molecule inhibitors for PTPN22.

Conclusions:

Small molecule PTPN22 inhibitors hold great promise for augmenting cancer immunotherapy efficacy.
Overcoming challenges in selectivity, potency, and in vivo efficacy is crucial for therapeutic application.
PTPN22 inhibition represents a promising strategy to improve outcomes in cancer immunotherapy.